Ensitrelvir postexposure prophylaxis for COVID-19: Translating trial efficacy into clinical practice

Conflict of interest statement

The author declares no conflicts of interest.

Funding

No funding was received for this work.

Ethical approval

Ethical approval was not required for this article because no human participants, patient data, or identifiable information were involved.

Author’s contributions

The author contributed to the conception, drafting, critical revision, and final approval of the manuscript.

Publisher’s note

The Publisher of the Journal remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Edited by Zhang Q, Lei Y, Pan Y

References

[1] Hayden FG, Shinkai M, Clark TW, Luetkemeyer AF, Sax PE, Hanage WP, et al. Ensitrelvir for Covid-19 postexposure prophylaxis in household contacts. N Engl J Med 2026; 394: 1905-1915.

[2] Hammond J, Yunis C, Fountaine RJ, Luscan G, Burr AM, Zhang W, et al. Oral nirmatrelvir-ritonavir as postexposure prophylaxis for COVID-19. N Engl J Med 2024; 391(3): 224-234. doi: 10.1056/NEJMoa2309002.

[3] Alpizar SA, Accini J, Anderson DC, Eysa B, Medina-Piñón I, Ohmagari N, et al. MOVe-AHEAD study group. Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial. J Infect 2023; 87(5): 392-402. doi: 10.1016/ j.jinf.2023.08.016.

[4] Shionogi & Co., Ltd. XOCOVA (ensitrelvir) prescribing information. [Online]. Available from: https://www.shionogi.com/content/dam/shionogi/si/products/pdf/xocova.pdf. [8 June 2026].

[5] Shionogi & Co., Ltd. Shionogi announces approval in Japan of a supplemental indication for Xocova (ensitrelvir fumaric acid) for the post-exposure prophylaxis of COVID-19. Available from: https://www.shionogi.com/global/en/news/2026/03/20260323_1.html. [8 June 2026].